218 related articles for article (PubMed ID: 21810919)
1. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.
Twitty CG; Jensen SM; Hu HM; Fox BA
Clin Cancer Res; 2011 Oct; 17(20):6467-81. PubMed ID: 21810919
[TBL] [Abstract][Full Text] [Related]
2. Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.
Yu G; Li Y; Cui Z; Morris NP; Weinberg AD; Fox BA; Urba WJ; Wang L; Hu HM
Sci Rep; 2016 Nov; 6():37558. PubMed ID: 27874054
[TBL] [Abstract][Full Text] [Related]
3. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
Coggin JH
Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.
Li Y; Wang LX; Pang P; Cui Z; Aung S; Haley D; Fox BA; Urba WJ; Hu HM
Clin Cancer Res; 2011 Nov; 17(22):7047-57. PubMed ID: 22068657
[TBL] [Abstract][Full Text] [Related]
5. Cross-reacting antigens in chemically induced sarcomas are fetal determinants.
Parker GA; Rosenberg SA
J Immunol; 1977 May; 118(5):1590-4. PubMed ID: 67142
[TBL] [Abstract][Full Text] [Related]
6. Autophagy adaptor protein p62/SQSTM1 and autophagy-related gene Atg5 mediate autophagosome formation in response to Mycobacterium tuberculosis infection in dendritic cells.
Seto S; Tsujimura K; Horii T; Koide Y
PLoS One; 2013; 8(12):e86017. PubMed ID: 24376899
[TBL] [Abstract][Full Text] [Related]
7. Serologic identification of multiple tumor-associated antigens on murine sarcomas.
Parker GA; Rosenberg SA
J Natl Cancer Inst; 1977 May; 58(5):1303-9. PubMed ID: 67211
[TBL] [Abstract][Full Text] [Related]
8. Changes in tumor-specific antigen expression during passage in vitro and in vivo of newly derived methylcholanthrene-induced sarcomas of BALB/C mice.
Law LW
Int J Cancer; 1980 Feb; 25(2):251-9. PubMed ID: 6156130
[TBL] [Abstract][Full Text] [Related]
9. Methylcholanthrene-induced mouse sarcomas express individually distinct major histocompatibility complex class I-associated peptides recognized by specific CD8+ T-cell lines.
Kono K; Petersson M; Ciupitu AM; Wen T; Klein G; Kiessling R
Cancer Res; 1995 Dec; 55(23):5648-55. PubMed ID: 7585649
[TBL] [Abstract][Full Text] [Related]
10. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action.
Evans R
Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the induction of contrasuppression by antisera against tumor-associated surface antigens on methylcholanthrene-induced sarcomas.
Flood PM; DeLeo AB; Old LJ; Gershon RK
Haematol Blood Transfus; 1983; 28():486-8. PubMed ID: 6222948
[No Abstract] [Full Text] [Related]
12. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.
Dudley ME; Roopenian DC
J Exp Med; 1996 Aug; 184(2):441-7. PubMed ID: 8760797
[TBL] [Abstract][Full Text] [Related]
13. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
Tseng CW; Monie A; Wu CY; Huang B; Wang MC; Hung CF; Wu TC
J Mol Med (Berl); 2008 Aug; 86(8):899-908. PubMed ID: 18542898
[TBL] [Abstract][Full Text] [Related]
14. Production of T-cell lines with inhibitory or stimulatory activity against syngeneic tumors in vivo. A preliminary report.
Mulé JJ; Forstrom JW; George E; Hellström I; Hellström KE
Int J Cancer; 1981 Nov; 28(5):611-4. PubMed ID: 6796530
[TBL] [Abstract][Full Text] [Related]
15. Generation of crossreacting tumor antigens in ascitic derivatives from murine methylcholanthrene-induced sarcomas.
Law LW
Int J Cancer; 1984 Apr; 33(4):547-51. PubMed ID: 6200449
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.
Aldarouish M; Wang H; Zhou M; Hu HM; Wang LX
J Exp Clin Cancer Res; 2015 Apr; 34(1):34. PubMed ID: 25886865
[TBL] [Abstract][Full Text] [Related]
17. Failure of immunogenic tumors to elicit cytolytic T cells in syngeneic hosts.
Nelson DS; Hopper KE; Blanden RV; Gardner ID; Kearney R
Cancer Lett; 1978 Aug; 5(2):61-7. PubMed ID: 308390
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens.
Cohen PA; Cohen PJ; Rosenberg SA; Mulé JJ
Cancer Res; 1994 Feb; 54(4):1055-8. PubMed ID: 7906197
[TBL] [Abstract][Full Text] [Related]
19. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.
Crowe NY; Smyth MJ; Godfrey DI
J Exp Med; 2002 Jul; 196(1):119-27. PubMed ID: 12093876
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
Ren H; Zhao S; Li W; Dong H; Zhou M; Cao M; Hu HM; Wang LX
J Immunother; 2014 Oct; 37(8):383-93. PubMed ID: 25198526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
